Clinical trial · Interventional
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-label Phase I/II Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patupilone trial for patients with recurrent glioblastoma, which are planned for re-operation. Objectives: prolongation of PFS compared to patients with re-operation only, Patupilone tumor concentrations, pharmacokinetic, Perfusion in MRI pre - and post Patupilone. Translational research of tumor tissue exposed to patupilone. * Trial with medicinal product
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma Planned for Reoperation | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patupilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression free survival
- timeFrame
- 3 years
- measure
- PFS, OS translational research
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion criteria: * Recurrent glioblastoma at least 2 cm in diameter after standard treatment (Surgery, Radiotherapy and Chemotherapy), which has to be completed at least three weeks earlier. * \> 18 years of age, KPS 70-100% * No liver disease, no malignancies (except curative treated skin tumors, DCIS of the breast and curative treated cervix carcinoma) * Lc \> 3000 und Tc \> 100 000, Hb\> 9, Bilirubin \</= 1.5mg/dl, AST/ALT less than 2.5 x upper limit, creatinine \</= 132umol/l * No pregnancy or breast feeding * Written Informed Consent prior to study entry * No reasons for incompliance * Reoperation planned Exclusion criteria: * KPS \< 70% * Radiotherapy- or Chemotherapy within 6 weeks * Enzyme inducing medication or St John's wort * Other study medication within 28 days * Other malignancies * Intolerance of Patupilone * Prior Patupilone * Neuropathy \> Grad 1 * Other life threatening illnesses * Acute or chronic liver diseases * HIV Infection * Known non-compliance in medication intake,inability to give informed consent * Cardiac problems (NYHA III oder IV) with uncontrolled insufficiency or angina pectoris * Active or uncontrolled infection * Pregnancy or breast feeding * Hematologic Growth Factors (without Erythropoetin) colostomy * Patients with uncontrolled diarrhea in the last 7 days prior to study entry.
References
Publications (0)
Data not yet available